Continental Gold Inc. (CNL:CA) Rises 6.99% for February 16

Equities Staff |

February 16 was a positive day for Continental Gold Inc. (CNL:CA) as its stock finished the day having gained 6.99% to hit a price of $5.66 a share. The company reached a market cap of 801.62 million and has 141.63 million shares outstanding. Continental Gold Inc. is a component of the the S&P/TSX SmallCap Index.

930,482 shares changed hands over the course of the day as compared to an average volume of 617,872 over the last 30 days for Continental Gold Inc..

Continental Gold Inc is engaged in the acquisition, exploration and development of its mineral properties in Colombia. Its properties include Berlin and Buritica.. The company makes its home in Toronto, ON, and is currently under the leadership of CEO Ari Benjamin Sussman.

Continental Gold Inc. has hit a high of $5.46 and reached a low of $1.40 over its last year of trading. The stock’s 50-day SMA is now $4.38 and 200-day SMA is $3.70. As for its price valuations, the P/E ratio is at 0 and P/B is now 2.54.

Want to invest with the experts? Subscribe to Equities Premium newsletters today! Visit to learn more about Guild Investment’s Market Commentary and Adam Sarhan’s Find Leading Stocks today.

The S&P/TSX SmallCap Index tracks over 200 Canadian small-cap stocks for cumulative performance. Relying on market cap weighting to calculate returns, it’s an index similar in composition to the Russell 2000, only focused on Canadian companies and much smaller in terms of its total membership. Widely recognized as the benchmark for small-cap Canadian stocks, the member companies must have a market cap between C$100 million and C$1.5 billion and an average share price of at least C$1.

To get more information on Continental Gold Inc. and to follow the company’s latest updates, you can visit the company’s profile page here: CNL:CA’s Profile. For more news on the financial markets and emerging growth companies, be sure to visit’s Newsdesk. Also, don’t forget to sign-up for our daily email newsletter to ensure you don’t miss out on any of our best stories.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth

IMV Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.

Private Markets

Quants Inc

Quants, Inc, a California Corporation, develops, markets and operates financial technology platforms and alternative investment products offering sophisticated risk management since 2010. The Company has primarily sharpened its focus with…


Voleo is a free download that allows you to form investment clubs with your friends, family, colleagues, classmates, teammates…basically anyone you know and trust. Invest and manage a stock portfolio…